Anti cd8 pacific orange clone rpa t8

Manufactured by BioLegend

Anti-CD8 Pacific-Orange (clone RPA-T8) is a fluorescently labeled monoclonal antibody that binds to the CD8 cell surface glycoprotein. CD8 is expressed on a subset of T cells and plays a role in the immune response.

Automatically generated - may contain errors

Lab products found in correlation

Anti cd3 v450 clone ucht1, by BD (2 mentions) Anti cd4 apc h7 clone rpa t4, by BD (2 mentions) Anti cd25 pe cy7 clone m a251, by BD (2 mentions) Anti cd127 pe cy5 clone ebiordr5, by Thermo Fisher Scientific (2 mentions) Anti cd56 pe clone b159, by BD (2 mentions) Anti cd19 apc clone hib19, by BD (2 mentions) Facscanto 2, by BD (2 mentions) Facsdiva software, by BD (2 mentions) Fortessa, by BD (1 mentions)

Close spelling variants of this product

Anti-CD8 (clone RPA-T8; CD8 (clone RPA-T8; Anti-CD8 (RPA-T8, Clone RPA-T8 RPA-T8 Pacific Orange Anti-CD8

2 protocols using anti cd8 pacific orange clone rpa t8

Comprehensive Immune Cell Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols

CD4⁺ T cells were defined as CD3+CD4⁺; CD8⁺ T cells were defined as CD3⁺CD8⁺; CD8⁺ naïve cells were defined as CD8⁺CD45RO-CD62L⁺; CD4 Tregs were defined as CD3⁺CD4⁺CD25^med-highCD127^low; CD4 conventional T cells (Tcons) were defined as CD3⁺CD4⁺CD25^low-negCD127^med-high; natural killer (NK) cells as CD56⁺CD3⁻; and B cells as CD19⁺. Aliquots of anti-coagulated whole blood (ethylenediaminetetraacetic acid [EDTA]) were incubated with fluorophore-conjugated monoclonal antibodies: anti-CD3 V450 (clone UCHT1, BD Biosciences), anti-CD4 APC-H7 (clone RPA-T4, BD Biosciences), anti-CD8 Pacific-Orange (clone RPA-T8, Biolegend), anti-CD25 PE-Cy7 (clone M-A251, BD Biosciences), anti-CD127 PE-Cy5 (clone eBioRDR5, eBioscience) for T-cell subsets; anti-CD56 PE (clone B159, BD Biosciences), anti-CD3 V450 (clone UCHT1, BD Biosciences) for NK/NKT cells, and anti-CD19 APC (clone HIB19, BD Biosciences) for B cells. RBC lysis with BD Pharm Lyse was performed either prior to or following incubation with conjugated antibodies. Flow cytometry analysis utilized FACSCanto II (BD Bioscience) or the Fortessa (BD Bioscience) and FACSDiva software (BD Bioscience). There was a change in the use of flow cytometry machines over the course of the study. Both flow cytometers were validated and results were comparable.

Koreth J., Kim H.T., Lange P.B., Poryanda S.J., Reynolds C.G., Rai S.C., Armand P., Cutler C.S., Ho V.T., Glotzbecker B., Yusuf R., Nikiforow S., Chen Y.B., Dey B., McMasters M., Ritz J., Blazar B.R., Soiffer R.J., Antin J.H, & Alyea EP I.I.I. (2018). Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results. Haematologica, 103(3), 522-530.

+ Open protocol

+ Expand

Comprehensive Immune Cell Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immune reconstitution assays: CD4+ T cells were defined as CD3+CD4+; CD4+ naïve cells were defined as CD4+, CD45RO⁻; CD4+ memory cells were defined as CD4+CD45RO+; CD8+ T cells were defined as CD3+CD8+; CD8+ naïve cells were defined as CD8+CD45RO⁻CD62L+; CD8+ memory cells were defined as CD8+CD45RO+; CD8+ terminal effector cells were defined as CD8+CD45RO⁻CD62L⁻; CD4 regulatory T cells (Treg) were defined as CD3+CD4+CD25^med-highCD127^low; NK cells as CD56+CD3⁻; and B cells as CD19+. Fifty μl whole blood (15% EDTA) in 5 ml polystyrene round-bottom reaction tubes was incubated with fluorophore-conjugated monoclonal antibodies: anti-CD3 V450 (clone UCHT1, BD Biosciences), anti-CD4 APC-H7 (clone RPA-T4, BD Biosciences), anti-CD8 Pacific-Orange (clone RPA-T8, Biolegend), anti-CD25 PE-Cy7 (clone M-A251, BD Biosciences), anti-CD127 PE-Cy5 (clone eBioRDR5, eBioscience), anti-CD62L APC (clone DREG-56, BD Biosciences), CD45RO FITC (clone UCHL1, BD Biosciences) for T cell subsets; anti-CD56 PE (clone B159, BD Biosciences), anti-CD3 V450 (clone UCHT1, BD Biosciences) for NK/NKT cells; anti-CD19 APC (clone HIB19, BD Biosciences) for B cells. RBC lysis with 500 μl 1× BD Pharm Lyse followed. Immune reconstitution flow cytometry analysis utilized FACSCanto II (BD Bioscience) and FACSDiva software (BD Bioscience).

Koreth J., Kim H.T., Lange P.B., Bindra B., Reynolds C.G., Chammas M.J., Armand P., Cutler C.S., Ho V.T., Glotzbecker B., Nikiforow S., Ritz J., Blazar B.R., Soiffer R.J., Antin J.H, & Alyea EP I.I.I. (2015). A Bortezomib-based Regimen Offers Promising Survival and Graft-vs.-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 21(11), 1907-1913.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!